BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33242366)

  • 1. Variation in Treatment of Children Hospitalized With New-Onset Systemic Juvenile Idiopathic Arthritis in the US.
    Peterson RG; Xiao R; James KE; Katcoff H; Fisher BT; Weiss PF
    Arthritis Care Res (Hoboken); 2021 Dec; 73(12):1714-1721. PubMed ID: 33242366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of first-line biologic initiation on glucocorticoid exposure in children hospitalized with new-onset systemic juvenile idiopathic arthritis: emulation of a pragmatic trial using observational data.
    Peterson RG; Xiao R; Katcoff H; Fisher BT; Weiss PF
    Pediatr Rheumatol Online J; 2021 Jul; 19(1):109. PubMed ID: 34225753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
    Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
    Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of pediatric rheumatologists and transitional care for juvenile idiopathic arthritis-associated uveitis: a retrospective series of 9 cases.
    Yamazaki S; Shimbo A; Akutsu Y; Takase H; Morio T; Mori M
    Pediatr Rheumatol Online J; 2020 Mar; 18(1):26. PubMed ID: 32293465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.
    Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ
    Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of systemic JIA: When do we need a biologic? Real world data of a single center.
    Adiguzel Dundar H; Acari C; Turkucar S; Unsal E
    Mod Rheumatol; 2021 May; 31(3):684-690. PubMed ID: 32343644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort.
    Zamora-Legoff JA; Krause ML; Crowson CS; Muskardin TW; Mason T; Matteson EL
    Clin Rheumatol; 2016 Jun; 35(6):1493-9. PubMed ID: 26825065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
    Davies R; Gaynor D; Hyrich KL; Pain CE
    Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
    Nigrovic PA; Beukelman T; Tomlinson G; Feldman BM; Schanberg LE; Kimura Y;
    Clin Trials; 2018 Jun; 15(3):268-277. PubMed ID: 29542334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription patterns for children with juvenile idiopathic arthritis in Michigan Medicaid: a comparison by prescriber type.
    Riebschleger MP; Van Mater HA; Cohn LM; Clark SJ
    Pediatr Rheumatol Online J; 2014; 12():38. PubMed ID: 25228851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
    Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S;
    Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revising diagnosis of juvenile idiopathic arthritis in adults: a single-center retrospective study.
    Felis-Giemza A; Chmurzyńska K; Kołodziejczyk B; Gazda A
    Rheumatol Int; 2023 Jul; 43(7):1307-1311. PubMed ID: 36859560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013.
    Janow G; Schanberg LE; Setoguchi S; Hasselblad V; Mellins ED; Schneider R; Kimura Y;
    J Rheumatol; 2016 Sep; 43(9):1755-62. PubMed ID: 27307527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumonia in children with juvenile idiopathic arthritis in Finland 1999-2014: a nationwide retrospective register linkage study.
    Salonen PH; Säilä H; Salonen JH; Linna M; Helminen M; Kauppi MJ
    Clin Exp Rheumatol; 2018; 36(3):502-507. PubMed ID: 29303705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid treatment in juvenile idiopathic arthritis.
    Batu ED
    Rheumatol Int; 2019 Jan; 39(1):13-27. PubMed ID: 30276425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.
    Kimura Y; Grevich S; Beukelman T; Morgan E; Nigrovic PA; Mieszkalski K; Graham TB; Ibarra M; Ilowite N; Klein-Gitelman M; Onel K; Prahalad S; Punaro M; Ringold S; Toib D; Van Mater H; Weiss JE; Weiss PF; Schanberg LE;
    Pediatr Rheumatol Online J; 2017 Apr; 15(1):23. PubMed ID: 28399931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.
    Beukelman T; Ringold S; Davis TE; DeWitt EM; Pelajo CF; Weiss PF; Kimura Y;
    J Rheumatol; 2012 Sep; 39(9):1867-74. PubMed ID: 22859354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
    Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
    Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.